search
clinical trial sites
Trends
- 1AI Clinical Monitoring Tool Reported to Cut Trial Costs by Millions▼AI Clinical Monitoring Tool Saves Millions in Trial Costs
An AI-powered clinical monitoring tool is reported to have saved millions of dollars in clinical trial costs, according to coverage in The Scientist. The tool is said to streamline monitoring of trial sites, reducing manual oversight work and associated expenses. The report highlights growing interest in applying artificial intelligence to make drug development faster and cheaper, though detailed figures and trial specifics were not provided.
- 2FDA Sets Single IRB Rule for Multisite Trials for December 2026●FDA Single IRB Rule for Multisite Trials Set for December 2026
The FDA's single institutional review board rule for multisite clinical trials will take effect in December 2026. Under the policy, one IRB will review studies conducted at multiple US sites, replacing the current patchwork of separate local reviews. Industry observers are weighing how the change will affect trial timelines, oversight responsibilities and costs for sponsors and research institutions.
- 3HIV patients with cancer travel farther for clinical trials▼HIV patients with cancer must travel farther than others to access clinical trials
Researchers at the University of Notre Dame have found that cancer patients living with HIV must travel greater distances than other patients to access clinical trials, adding barriers to care for a group already facing health disparities. The finding highlights geographic inequities in trial access and raises questions about how trial sites are distributed across the country.
- 4Moleculin Closes Enrollment in MIRACLE Acute Myeloid Leukemia Trial●Enrollment Closed: What Moleculin’s MIRACLE Trial Teaches About AML Site Execution
Moleculin Biotech has closed enrollment in its MIRACLE trial for acute myeloid leukemia, a step that shifts attention from recruiting patients to follow-up and data collection. Commentary around the milestone is focusing on what the trial's execution across clinical sites reveals about running complex AML studies. Observers in the oncology and biotech community are watching for next results.
- 5
Keros Therapeutics has dosed the first patient in a Phase 2 clinical trial of rinvatercept, an investigational therapy for Duchenne muscular dystrophy. The milestone marks the start of patient enrollment in the study, a key step in testing whether the drug can benefit people with the progressive muscle-wasting disease. Details on trial sites and timelines have not been widely reported yet.
- 6EDC Query Automation Weighed Against Site Capacity●EDC Query Automation: Balancing Coverage With Site Capacity
Clinical trial data professionals are examining how far electronic data capture query automation can be pushed before it outpaces the capacity of research sites to respond. The discussion centres on balancing broad automated query coverage against the workload burden automation places on site staff, and what a workable middle ground looks like for trial operations teams.